ClinicalTrials.govpublic full text
Phase II ABT-888 With Cyclophosphamide
ovarian cancer, primary peritoneal cancer, serous carcinoma cancer, triple-negative breast cancer, fallopian tube cancer, parp inhibitor, brca mutations, dna damage repair, pharmacodynamics, metronomic cyclophosphamide, breast cancer, peritoneal cancer
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 801943
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.